|Day Low/High||92.85 / 94.15|
|52 Wk Low/High||58.59 / 95.44|
Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.
Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...
Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company's proposed combination with Bristol-Myers Squibb Company (NYSE: BMY).
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low...
How can stocks rally with money coming out so swiftly? Jim Cramer says to take a look at the 5 best performing stocks in the Dow for the first quarter.
Jim Cramer takes a look at Williams-Sonoma, Fortive, Western Digital, Goodyear Tire & Rubber, Celgene, Welltower, Box and Twitter.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.
Celgene Corporation (NASDAQ:CELG) and Lotus Pharmaceutical Co., Ltd.
Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene's proprietary IMiD ® medications,...
Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.
Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.
Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).
Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets
Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).
Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.
However, the RMPIA did not see as much improvement last month as some other market indices.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.